Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 3/20 | 0.76 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.76 |
| ▸ | PTGES | O14684 | 1/20 | 0.76 |
| ▸ | LMNA | P02545 | 1/20 | 0.76 |
| ▸ | LTA4H | P09960 | 1/20 | 0.76 |
| ▸ | GAA | P10253 | 1/20 | 0.76 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.76 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.76 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.76 |
| ▸ | LOX | P28300 | 1/20 | 0.76 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.76 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.76 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15502039 | 1.00 | ALOX5 (0.76) | ALOX5CYP1A2PTGESLMNALTA4H | |
| Ammonia Solution, Strong SCHEMBL6388069 | 0.98 | ALOX5 (0.74) | ALOX5CYP1A2PTGESLMNALTA4H | |
| Ammonia Solution, Strong SCHEMBL2393143 | 0.98 | ALOX5 (0.74) | ALOX5CYP1A2PTGESLMNALTA4H | |
| Methylamine SCHEMBL9601432 | 0.97 | ALOX5 (0.77) | ALOX5CYP1A2PTGESLMNALTA4H | |
| SCHEMBL2397431 | 0.92 | ALOX5 (0.66) | ALOX5CYP1A2PTGESLMNALTA4H | |
| Tetrylammonium SCHEMBL2399019 | 0.91 | ALOX5 (0.64) | ALOX5CYP1A2PTGESLMNALTA4H | |
| SCHEMBL1444813 | 0.88 | ALOX5 (0.76) | ALOX5CYP1A2PTGESLMNALTA4H | |
| Zileuton SCHEMBL4209 | 0.87 | ALOX5 (1.00) | ALOX5CYP1A2PTGESLMNALTA4H | |
| Zileuton SCHEMBL8876686 | 0.87 | ALOX5 (1.00) | ALOX5CYP1A2PTGESLMNALTA4H | |
| Zileuton SCHEMBL126156 | 0.87 | ALOX5 (1.00) | ALOX5CYP1A2PTGESLMNALTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1363618-B1 | PHARMACEUTICAL COMPOSITION FOR TREATING MULTIPLE SCLEROSIS | NEU INGO S (DE) | 2006-05-03 | — | — | EP | claimed |
| US-20050020665-A1 | Pharmaceutical composition for treating multiple sclerosis | NEU INGO (DE) | 2005-01-27 | — | — | US | claimed |
| EP-1363618-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING MULTIPLE SCLEROSIS | Neu, Ingo, S. (DE) | 2003-11-26 | — | — | EP | claimed |
| WO-2002062332-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING MULTIPLE SCLEROSIS | NEU INGO S (DE) | 2002-08-15 | — | — | WO | claimed |
| WO-2014115098-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DISEASES AND INFLAMMATION | KANDULA MAHESH (IN) | 2014-07-31 | — | — | WO | disclosed |
| US-20140171445-A1 | TREATMENT AND PREVENTION OF DISEASES MEDIATED BY MICROORGANISMS VIA DRUG-MEDIATED MANIPULATION OF THE EICOSANOID BALANCE | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2014-06-19 | — | — | US | disclosed |
| US-20110209699-A1 | COMBINATION OF DEHYDROEPIANDROSTERONE OR DEHYDROEPIANDROSTERONE-SULFATE WITH A LIPOXYGENASE INHIBITOR FOR TREATMENT OF ASTHMA OR CHRONIC OBSTRUCTIVE PULMONARY DISEASE | EPIGENESIS PHARMACEUTICALS, LLC | 2011-09-01 | — | — | US | disclosed |
| US-20110209699-A1 | COMBINATION OF DEHYDROEPIANDROSTERONE OR DEHYDROEPIANDROSTERONE-SULFATE WITH A LIPOXYGENASE INHIBITOR FOR TREATMENT OF ASTHMA OR CHRONIC OBSTRUCTIVE PULMONARY DISEASE | EPIGENESIS PHARMACEUTICALS, LLC | 2011-09-01 | — | — | US | disclosed |
| WO-2011036680-A2 | IMPROVED PROCESS FOR THE PREPARATION OF (±)-1-(1-BENZO[B]THIEN-2-YLETHYL)-1-HYDROXYUREA | MSN LABORATORIES LIMITED (IN) | 2011-03-31 | — | — | WO | disclosed |
| US-7563790-B2 | Pyridazine derivatives | MERCK PATENT GMBH (DE) | 2009-07-21 | — | — | US | disclosed |
| US-7544684-B2 | Hydrazono-malonitriles | MERCK PATENT GMBH (DE) | 2009-06-09 | — | — | US | disclosed |
| US-7470687-B2 | Aryl oximes | MERCK PATENT GMBH (DE) | 2008-12-30 | — | — | US | disclosed |
| EP-1363618-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING MULTIPLE SCLEROSIS | Neu, Ingo, S. (DE) | 2003-11-26 | — | — | EP | disclosed |
| WO-2002062332-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING MULTIPLE SCLEROSIS | NEU INGO S (DE) | 2002-08-15 | — | — | WO | disclosed |
| US-5250565-A | Must incorporate a metabolically cleavable leaving group; pro-drugs; administering to mammals | ABBOTT LABORATORIES (US) | 1993-10-05 | — | — | US | disclosed |
| EP-0279263-B1 | INDOLE, BENZOFURAN, BENZOTHIOPHENE CONTAINING LIPOXYGENASE INHIBITING COMPOUNDS | ABBOTT LABORATORIES (US) | 1993-08-04 | — | — | EP | disclosed |
| EP-0416609-A2 | Benzo[b]thiophene-containing lipoxygenase-inhibiting compounds | ABBOTT LABORATORIES (US) | 1991-03-13 | — | — | EP | disclosed |
| US-4873259-A | Indole, benzofuran, benzothiophene containing lipoxygenase inhibiting compounds | ABBOTT LABORATORIES (US) | 1989-10-10 | — | — | US | disclosed |
| US-4822809-A | ENZYME INHIBITORS | ABBOTT LABORATORIES (US) | 1989-04-18 | — | — | US | disclosed |
| EP-0279263-A2 | Indole, benzofuran, benzothiophene containing lipoxygenase inhibiting compounds | ABBOTT LABORATORIES (US) | 1988-08-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020665-A1 | Pharmaceutical composition for treating multiple sclerosis | NR1H3, NR1H2, NR1H4 | ALOX5 1826/4885CYP1A2 1042/4885PTGES 3679/4885 |
| US-20110209699-A1 | COMBINATION OF DEHYDROEPIANDROSTERONE OR DEHYDROEPIANDROSTERONE-SULFATE WITH A LIPOXYGENASE INHIBITOR FOR TREATMENT OF ASTHMA OR CHRONIC OBSTRUCTIVE PULMONARY DISEASE | HSD11B2, CYP17A1, ALOX5 | ALOX5 3/4885CYP1A2 249/4885PTGES 57/4885 |
| US-20140171445-A1 | TREATMENT AND PREVENTION OF DISEASES MEDIATED BY MICROORGANISMS VIA DRUG-MEDIATED MANIPULATION OF THE EICOSANOID BALANCE | ALOX5, ALOX15, ALOX15B | ALOX5 1/4885CYP1A2 318/4885PTGES 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.